1171 related articles for article (PubMed ID: 21090814)
21. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.
Schirmer A; Kennedy J; Murli S; Reid R; Santi DV
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4234-9. PubMed ID: 16537514
[TBL] [Abstract][Full Text] [Related]
22. Identification of small-molecule inhibitors of the JIP-JNK interaction.
Chen T; Kablaoui N; Little J; Timofeevski S; Tschantz WR; Chen P; Feng J; Charlton M; Stanton R; Bauer P
Biochem J; 2009 May; 420(2):283-94. PubMed ID: 19243309
[TBL] [Abstract][Full Text] [Related]
23. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
24. Novel strategies for inhibition of the p38 MAPK pathway.
Zhang J; Shen B; Lin A
Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
[TBL] [Abstract][Full Text] [Related]
25. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
Chuaqui C; Deng Z; Singh J
J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
[TBL] [Abstract][Full Text] [Related]
26. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
[TBL] [Abstract][Full Text] [Related]
27. The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity.
Shaw D; Wang SM; Villaseñor AG; Tsing S; Walter D; Browner MF; Barnett J; Kuglstatter A
J Mol Biol; 2008 Nov; 383(4):885-93. PubMed ID: 18801372
[TBL] [Abstract][Full Text] [Related]
28. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
29. The design, annotation, and application of a kinase-targeted library.
Xi H; Lunney EA
Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
[TBL] [Abstract][Full Text] [Related]
30. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
31. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
33. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
[TBL] [Abstract][Full Text] [Related]
34. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.
Moss N; Breitfelder S; Betageri R; Cirillo PF; Fadra T; Hickey ER; Kirrane T; Kroe RR; Madwed J; Nelson RM; Pargellis CA; Qian KC; Regan J; Swinamer A; Torcellini C
Bioorg Med Chem Lett; 2007 Aug; 17(15):4242-7. PubMed ID: 17560108
[TBL] [Abstract][Full Text] [Related]
35. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
36. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
[TBL] [Abstract][Full Text] [Related]
37. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
38. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action.
Navratilova I; Macdonald G; Robinson C; Hughes S; Mathias J; Phillips C; Cook A
J Biomol Screen; 2012 Feb; 17(2):183-93. PubMed ID: 22068706
[TBL] [Abstract][Full Text] [Related]
39. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
40. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]